Posted on May 28, 20265/28/26
Bridging Evidence Gaps in mCRPC: Highlighting the Potential of Talazoparib plus Enzalutamide
Posted on February 11, 20262/11/26
Demonstrating the Clinical and Economic Value of Efgartigimod for AChR‑Positive gMG in Canada
Posted on October 24, 202510/24/25
How a Strategic Global HEOR Package Drives Market Access and Pricing Success
Posted on October 16, 202510/16/25
Seeing the Whole Picture: How Value & Evidence Generalists Drive Strategic Impact and Client Success
Posted on October 16, 202510/16/25
Identifying Challenges and Solutions for Indirect Comparisons in Myasthenia Gravis
Posted on September 25, 20259/25/25
Reimagining Pharma Commercialization with AI Agents
Posted on August 19, 20258/19/25
Expanding the Evidence: Real-World Insights into CDK4/6i Use in Elderly and BIPOC Patients with Metastatic Breast Cancer
Posted on July 18, 20257/18/25
Bridging the Evidence Gap in Hereditary Angioedema (HAE): Indirect Comparison Highlights Garadacimab’s Potential
Posted on June 6, 20256/6/25